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Abstract
Nanotechnology has brought a variety of new possibilities into biological discovery and clinical practice. In particu-
lar, nano-scaled carriers have revolutionalized drug delivery, allowing for therapeutic agents to be selectively tar-
geted on an organ, tissue and cell specific level, also minimizing exposure of healthy tissue to drugs. In this review
we discuss and analyze three issues, which are considered to be at the core of nano-scaled drug delivery systems,
namely functionalization of nanocarriers, delivery to target organs and in vivo imaging. The latest developments on
highly specific conjugation strategies that are used to attach biomolecules to the surface of nanoparticles (NP) are
first reviewed. Besides drug carrying capabilities, the functionalization of nanocarriers also facilitate their transport
to primary target organs. We highlight the leading advantage of nanocarriers, i.e. their ability to cross the blood-
brain barrier (BBB), a tightly packed layer of endothelial cells surrounding the brain that prevents high-molecular
weight molecules from entering the brain. The BBB has several transport molecules such as growth factors, insulin
and transferrin that can potentially increase the efficiency and kinetics of brain-targeting nanocarriers. Potential
treatments for common neurological disorders, such as stroke, tumours and Alzheimer’s, are therefore a much
sought-after application of nanomedicine. Likewise any other drug delivery system, a number of parameters need
to be registered once functionalized NPs are administered, for instance their efficiency in organ-selective targeting,
bioaccumulation and excretion. Finally, direct in vivo imaging of nanomaterials is an exciting recent field that can
provide real-time tracking of those nanocarriers. We review a range of systems suitable for in vivo imaging and
monitoring of drug delivery, with an emphasis on most recently introduced molecular imaging modalities based
on optical and hybrid contrast, such as fluorescent protein tomography and multispectral optoacoustic tomogra-
phy. Overall, great potential is foreseen for nanocarriers in medical diagnostics, therapeutics and molecular target-
ing. A proposed roadmap for ongoing and future research directions is therefore discussed in detail with emphasis
on the development of novel approaches for functionalization, targeting and imaging of nano-based drug delivery
systems, a cutting-edge technology poised to change the ways medicine is administered.
Introduction
Nanotechnology has brought a new generation of light-
weight materials with superior mechanical and electrical
properties. Engineered nanoparticles (NPs) are normally
embedded in the matrix of other composites to enhance
certain characteristics. Biology and medicine, however,
usually employ dispersed NPs, for instance as fluores-
cent biological labels [1-3], drug and gene delivery
agents [4,5], bio-detection of pathogens [6], detection
of proteins [7], probing of DNA structure [8], tissue
engineering [9,10], tumour destruction via heating
(hyperthermia) [11], separation and purification of biolo-
gical molecules and cells [12], magnetic resonance ima-
ging (MRI) contrast enhancement [13] and phagokinetic
studies [14]. The ability of the engineered nanoparticles
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provides them with a distinct advantage over other poly-
meric or macromolecular substances.
While the advent of nanotechnology made its first
mark on consumer products, until recently, very little
was known about their potential medical applications.
NPs have long been noticed to pass across the BBB [15],
a tightly packed layer of endothelial cells surrounding
the brain that prevents high-molecular weight molecules
from passing through. This in itself provides a substan-
tial advantage for drug delivery systems across the BBB,
which can pave the way for effective treatments of many
central nervous system disorders. This feature, however,
was not fully exploited till two decades later.
Despite the advances and breakthroughs in nanotech-
nology-based approaches, their efficacy towards the
treatment of neurological disorders, like brain tumour,
stroke, Alzheimer’s disease, have been largely con-
strained. As such, keeping in mind the paucity of thera-
pies for such debilitating disorders, advances in the
targeting of drugs to the central nervous system (CNS)
will be the main stay for the future success and develop-
ment of nanotechnology-based diagnostics (application
of NPs in therapy and diagnostics) in neurology. To this
end, efficient delivery of many potentially therapeutic
and diagnostic compounds to specific areas of the brain
is hindered by the BBB, the blood cerebrospinal fluid
barrier (BCSF), or other specialized CNS barriers [16].
As a result, the global market for drugs for the CNS is
greatly under-penetrated and would have to grow by
over 500% just to be comparable to the global market
for cardiovascular drugs [17]. Only a small class of
drugs or small molecules with high lipid solubility and
low molecular mass of < 400-500 Daltons actually goes
across the BBB [18]. For instance, in a recent study of
the comprehensive medicinal chemistry (CMC) database
[19], over 7,000 drugs were analyzed and only 5% of
these drugs affected the CNS, treating primarily depres-
sion, schizophrenia, and insomnia. The average molecu-
lar mass of the CNS active drug was 357 Daltons.
Another similar study found 12% of drugs active upon
t h eC N S ,b u to n l y1 %o ft h et o t a ln u m b e r so fd r u g s
were active in the CNS for diseases other than affective
disorders [20]. Modern ageing societies require therefore
a broader spectrum of treatments for neurological
disorders.
Functionalization of NPs is indeed the first and per-
haps foremost step towards nano-scale drug delivery
systems. NPs should inherit a number of desirable char-
acteristics from their functionalization. Drug-carrying
capabilities are as important as transport, organ target-
ing and eventual excretion. Affinity of functional groups
to tissue specific transport methods is clearly a challen-
ging problem. It is known that some transport
molecules such as growth factors, insulin and transferrin
can potentially increase the efficiency and kinetics of
drugs across a range of tissues.
Once nanomaterials are enhanced with drug-carrying
and transport capabilities, in vivo imaging markers, such
as fluorescent dyes for optical imaging, is the next land-
mark to achieve. No review on functionalization of
nanocarriers is complete without mentioning imaging
technologies capable of their effective visualization.
Beyond improvements in overall image quality and spa-
tial resolution, imaging modalities have been entrusted
with the challenge of capturing dynamic processes invol-
ving various biological system components as well as
their respective interactions. For example, the ability to
resolve and monitor transmigration ability of various
types of biomolecules across the BBB in vivo is a daunt-
ing challenge. In this context, we give a special attention
to the most recent developments in the field of fluores-
cence-based imaging techniques that have become an
integral part of modern biological discovery process,
especially in the pre-clinical small-animal-based
research. Initially, fluorescence imaging was limited to
ex vivo and in vitro applications with an exception of
several intravital microscopy and photographic imaging
approaches [21-23]. Although helpful in some cases,
these methods fall short to the potential of more recent
trans-illumination and tomographic techniques that
allow non-invasive fluorescence images in vivo [24].
Powerful capabilities are found when those techniques
are co-registered with precise in vivo anatomical views
of the brain provided by MRI or X-ray computed tomo-
graphy (CT). An additional enormous potential lie
ahead with the recent advances of high resolution
optoacoustic molecular imaging approaches, such as
multispectral optoacoustic tomography (MSOT) [25].
All these are expected to facilitate the development of
novel imaging-based diagnostic and therapeutic nanop-
robes for early diagnosis and therapy of various disor-
ders of the brain following systematic administration. In
this review, we highlight some of the ongoing trends in
molecular tomographic imaging of live animals and pre-
sent insights into exploiting targeting of brain tumours
for therapeutic and diagnostics purpose.
Next section will discuss the physiology of BBB, which
plays an important role in designing novel platforms to
enable access to the brain.
Blood Brain Barrier: A gateway to neurological
diseases
Treatment of neurological diseases such as brain
tumours, inborn metabolic errors (e.g., lysosomal storage
diseases), infectious diseases and aging, is a daunting
challenge due to the unique environment of CNS
[26,27]. The advancement of pharmacological drug
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tence of protective barriers which restricts the passage
of foreign particles into the brain. Therefore, the effi-
cient design of non-invasive nanocarrier systems that
can facilitate controlled and targeted drug delivery to
t h es p e c i f i cr e g i o n so ft h eb r a i ni sam a j o rc h a l l e n g ei n
drug development and delivery for the neurological dis-
eases [28,29]. It becomes crucial to understand the
structural composition as well as the functions of the
factors that regulate permeability of the substances
across the BBB. For that reason, we will briefly discuss
the main transporters that mediate the transport of sub-
stances across the brain.
Physiology of the Blood Brain Barrier
Figure 1 gives an overview of the two main immunologi-
cal barriers, namely BBB and BCSF and their different
components. We can see how BBB acts as a neuropro-
tective shield by protecting the brain from most sub-
stances in the blood, supplying brain tissues with
nutrients, and filtering harmful compounds from the
brain back to the bloodstream [30]. BBB is constituted
by the brain endothelial cells which form the anatomical
substrate called cerebral microvascular endothelium. It
regulates the transport of solutes and other substances
including drugs in and out of the brain, leukocyte
migration, and maintains the homeostasis of the brain
microenvironment, which is crucial for neuronal activity
and proper functioning of CNS. The cerebral microvas-
cular endothelium, together with astrocytes, pericytes,
neurons, and the extracellular matrix, constitute a “neu-
rovascular unit” that is essential for the health and func-
tion of the CNS [31]. The transport of solutes and other
substances across BBB is strictly constrained through
both physical tight junctions (TJs) and adherents junc-
tions (AJs) and metabolic barriers (enzymes, diverse
transport systems) and hence excluding very small, elec-
trically neutral and lipid soluble molecules. Thus, con-
ventional pharmacological drugs or chemotherapeutic
agents are unable to pass through the barrier.
TJs between endothelial cells of the BBB possess also
an intricate complex of transmembrane proteins (junc-
tional adhesion molecule-1 (JAM-1), occludin, and clau-
dins) with cytoplasmic accessory proteins (zonula
Figure 1 Overview of the two main barriers in the CNS. blood-brain barrier and blood cerebrospinal fluid barrier (BCSF). ISF: Interstitial Fluid.
CSF: Cerebrospinal fluid. Adapted from [17,18].
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7H6) and hence acts as physiological and pharmacologi-
cal barrier, thereby preventing influx of molecules from
the bloodstream into the brain. As shown in Figures 1
and 2, BBB is characterized by two membranes, namely
luminal and abluminal, facing blood capillary and brain
interstitial fluids (ISF), respectively. Another especial
feature of BBB is the structural differences that exist
between the endothelia of the brain capillaries and
endothelia in other capillaries, such as tight junctions
between adjacent endothelial cells [31,32], a lack of
fenestrations (perforations) and a lack of pinocytotic
vesicles [33-38]. Furthermore, in addition to the BBB
and BCSF, there exists other CNS barrier shielding the
delicate brain tissue from the outer world, but which
m a yp l a yar o l ei nd r u gt r a n s p o r t ,s u c ha st h eb l o o d
tumour barrier and the blood retina barrier [39,40],
formed of pigment epithelium enclosing the retina, and
thereby acting as a barrier interface between the sys-
temic blood vessels of the neighbouring choroid and the
retina. Finally targeting of tumour tissue is often con-
stricted by the blood tumour barrier [39].
Moreover, BCSF is the second important feature of
the CNS next to the BBB, and is formed by the
epithelial cells of the choroid plexus. BCSF controls the
penetration of molecules within the interstitial fluid of
the brain parenchyma by closely regulating the exchange
of molecules between the blood and CSF. Previous
reports have demonstrated the following mechanisms of
transport pertaining to the choroid plexus: facilitated
diffusion (efflux) and active transport into the CSF, as
well as active transport (efflux) from CSF to the blood
[41-43].
Role of efflux transporters
The treatment of intractable CNS disorders such as
HIV, dementia, epilepsy, CNS-based pain, meningitis
and brain cancers depend mainly on the ways to achieve
higher drug concentration in the targeted tissues of the
brain. The ability of a substance to penetrate the BBB or
be transported across BBB is mainly dependent on its
physiochemical properties. The total brain exposure,
and thus the pharmacological efficacy of a drug or drug
candidate, depends on its drug uptake which in turn
depends on a combination of factors, including the phy-
sical barrier presented by the BBB and the BCSF and
the affinity of the substrate for specific transport systems
located at both sides of these interfaces [26,27]. The
Figure 2 Potential transport mechanisms across BBB. Diffusion and active transport as the main transport mechanisms (adapted from [42]).
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brain penetration as well as the intra- and extracellular
distribution of a variety of endogenous and exogenous
compounds [28].
The efflux transporters role, both as a homeostatic
agents against endogenous substances and protective
agents against the exogenous substances, have been
extensively studied and three classes of transporters
have been implicated in the efflux of drugs from the
brain: multidrug resistance transporters, monocarboxylic
acid transporters, and organic ion transporters [44].
Kabanov et al. [45] have reviewed the inhibition of efflux
transporters by Pluronic® block copolymers to enhance
the penetration of drugs for CNS delivery. Drug efflux
transporters not only cause elimination of the drugs
from the brain, but also affects its absorption and tissue
distribution [46]. Owing to the growing emphasis on
identification and discovery of influx transport proteins
(from blood to brain) and efflux transport proteins
(from brain to blood) in last years, BBB is now consid-
ered to be a dynamic interface that controls the influx
and efflux of a wide variety of substances, including
endogenous nutrients and exogenous compounds to
maintain a favourable environment for the CNS [47].
Deguchi and co-workers demonstrated that the rat
organic anion transporter 3 (rOat3) mediated brain-to-
blood transport of uremic toxins, as well as that rat
organic anion transporting polypeptide (rOatp2) is
involved in efflux of 3-carboxy-4-methyl-5-propyl-2-fur-
anpropionate [48]. Sun and co-workers investigated the
transport of carbamazepine and drug interactions with
cultured rat brain microvascular endothelial cells
(rBMEC) as an in vitro m o d e lo ft h eB B B[ 4 9 ] .T h e y
concluded that some specific ABC (ATP-binding cas-
sette, ABC) efflux transporters may be involved in the
transport of carbamazepine across the BBB.
The fact that many of the lipophilic drugs show negli-
gible brain uptake can be attributed to the substrates of
drug efflux transporters such as the organic anion trans-
porting polypeptides and the BBB active drug efflux
transporters of the ATP-binding cassette gene family,
e.g. P-glycoprotein (Pgp), multidrug resistance proteins
(MRPs) and breast cancer resistance protein (BCRP)
[45,48,50-53], that are overexpressed by the endothelial
or epithelial cells of these barriers [52]. The combined
action of these carrier systems results in rapid efflux of
xenobiotics from the CNS and they also account for the
cellular localization, specificity, regulation, and potential
inhibition at the BBB and BCSF barriers.
Efflux transporters act as a major impediment factor
to CNS access by restricting a number of solutes. The
future of CNS drug delivery is highly dependent on
novel strategies towards modulation of these efflux
transporters by designing nanocarriers with tuned
affinity for these transporters [45,52,53]. The following
section brings a more detailed account of transport
mechanisms.
Mechanisms of transport in and out from the
brain
A schematic overview of transport mechanisms across
the BBB is shown in Figure 2. There are different
mechanisms by which solutes move across membranes
in and out of the brain; but nevertheless, all these differ-
ent mechanisms can be categorized into two basic
forms. Firstly, the transport may occur due to diffusion,
either simply diffusion or facilitated transport across
aqueous channels. The primary bioenergy comes from a
concentration gradient across the membranes, between
cells (i.e., paracellular) or across cells (i.e., transcellular).
This passive diffusion accounts for the transport of
solutes through the cell membrane, depending upon size
and lipophilicity of the substances [54]. Secondly, active
transport is mediated by a carrier such as proteins. The
movement may be caused due to the molecular affinity,
fluid streams or magnetic fields.
Transports of solutes, drugs and other particles follow
different mechanisms as shown in Figure 2 and dis-
cussed shortly. Cell migration, in particular that from
blood leukocytes like monocytes/macrophages, and T
cells circulating through the capillary bed may cross
through the BBB driven by chemotaxis, and thereby
modifying the functionality of tight junctions [55].
Carrier mediated transport (CMT) or carrier-mediated
influx are forms of diffusion which may be passive or
active, depending on the context, and involve the unidir-
ectional transport of drugs from the blood to the brain.
It is mainly instrumental in the transport of many essen-
tial polar molecules, with the help of carrier systems or
transporters, such as glucose (GLUT1 glucose transpor-
ter), amino acids (the LAT1 large neutral amino acid
transporter, the CAT1 cationic amino acid transporter),
carboxylic acids (the MCT1 monocarboxylic acid trans-
porter) and nucleosides (the CNT2 nucleoside transpor-
ter) into the brain.
Active efflux transport or carrier mediated efflux
involve extrusion of drugs from the brain in the pre-
sence of efflux transporters such as P-glycoprotein, mul-
tidrug resistance protein protein, breast cancer
resistance protein and other transporters [56]. In con-
trast to the carrier mediated transport, the active efflux
transport causes the active efflux of drugs from brain
back to blood. It acts as a major obstacle in pharmaco-
logical drug delivery to the CNS. Interestingly, Banks
et al. demonstrated that endogenous peptides like Tyr-
Pro-Trp-Gly-NH2, transported from the brain to the
blood by peptide transport system-1 (PTS-1), are trans-
ported via active efflux [57].
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the transport of macromolecules like peptides and pro-
teins across the BBB by conjugating the substance with
ligands such as lactoferrin, transferrin and insulin
[58-60]. It is an important transport mechanism of pre-
dominant interest in drug delivery. Next, adsorptive
mediated transport is a type of endocytosis induced by
conjugating the particle to cationised ligands or peptides
such as albumin [61,62]. Due to electrostatic interaction
with the anionic sites present on the membrane, the
cationised ligand conjugated NPs takes the adsorptive
mediated transport to enter the brain.
Finally, tight junction (TJ) modulation is caused by the
relaxation of junctions, which facilitates selective aqu-
eous diffusion across paracellular junctions in the BBB.
Mahajan et al. reported the modulation of tight junction
using methamphetamine [63]. Further, they also demon-
strated modulation of TJs using Morphine and HIV-1
Tat via the activation of pro-inflammatory cytokines,
intracellular Ca2+ release, and activation of myosin light
chain kinase [64]. Their studies revealed decreased
transendothelial electric resistance and enhanced trans-
endothelial migration across the BBB. Similar observa-
tions are known about cocaine on BBB permeability,
which indeed worsen HIV dementia. Further studies are
needed towards the development of novel anti-HIV-1
therapeutics that target specific TJ proteins, such as
ZO-1, JAM-2, Occludin, Claudin-3 and Claudin-5.
Along with the normal physiological delivery methods,
a fascinating approach was recently developed using
ultrasound-mediated molecular delivery. For instance,
see e.g. work by Choi et al. demonstrating deposition of
gadolinium through ultrasound-induced blood-brain
barrier (BBB) openings in the murine hippocampus [65].
One important question in nano drug delivery, how-
ever often neglected, is about the fate of the nanocar-
riers themselves. What happens when nanocarriers
(hopefully still carrying the drugs) succeeded in getting
access to the central nervous system via BBB? What are
the underlying mechanisms that control how these
nanocarriers release the therapeutic drugs upon reaching
the CNS or the target region? Many of these mechan-
isms are still not well understood. Dramatic differences
can be obtained depending on functionalization,
dosages, administration and so on. The main mechan-
isms involving active targeting are shown in Figure 3.
BBB permeability of drugs can be highly increased by
active targeting, a non invasive way to transport drugs
to target organs using site-specific ligands. Nanocarriers
conjugated to ligands capable of recognizing brain capil-
lary endothelial cells and cerebral tumoural cells have
emerged as a major breakthrough in CNS drug delivery
and Neuro-oncology in particular [66]. The role of
endocytosis in targeted brain delivery has been recently
reviewed by Bareford et al. and they predicted that by
efficient targeting of conjugated nanocarrier systems to
the endolysosomal pathway; significant improvement of
the drug delivery for the treatment of lysosomal storage
diseases, cancer, and Alzheimer’s disease can be accom-
plished. Next, we will discuss about the two main
mechanisms of endocytosis mediated transport of nano-
carrier systems [67].
Receptor mediated endocytosis
Receptor mediated endocytosis (RME) or clathrin-
dependent endocytosis is a highly specific and energy
mediated transport enabling eukaryotic cells to selective
uptake macromolecules as specific cargo. For the BBB
receptor-specific ligands have also been shown to
be very effective to transport endogenous peptides
like insulin and transferrin, albumin, and opioid peptides
e.g. deltorphins, [D-penicillamine 2,5] enkephalin
(DPDPE) and deltorphin II [68-72]. That is why recep-
tor-mediated drug delivery, is also a promising Trojan
horse approach for the release of therapeutics into neu-
ronal cells, and tissues. Nanocarriers conjugated to dif-
ferent types of ligands of cell surface receptors
expressed on brain endothelial cells, can accumulate and
eventually be internalized by cells on the vascular side of
the brain through the mechanism of receptor-mediated
endocytosis. By direct and indirect conjugation of endo-
genous and chimeric peptides to nanocarriers or recep-
tors of BBB, significant improvement in drug delivery
has been reported [66,73,74]. The desirable fate of tar-
geted receptors after endocytosis can be seen in the in
the following way. Upon binding to the receptors, the
ligand conjugated nanocarrier gets collected in specia-
lized areas of the plasma membrane known as coated
pits. These clathrin coated pits invaginate to form
coated vesicles, upon endosomal processing of the vesi-
cle, clathrin and associated proteins dissociate from the
vesicle membrane (early endosome), to form new coated
pits at the cell surface [70]. The receptor dissociates
from the ligand conjugated nanocarrier due to the acidi-
fication of the vesicle in the late endosome, and the
nanocarrier complex degrades, hence releasing the drug
to the cell.
In addition three different mechanisms supporting the
ligand conjugated nanocarrier based transport of drugs
such as neuropeptides have been proposed: (i) the
adsorption of uptake promoting apolipoproteins, (ii) the
modulation of tight junctions, and (iii) the inhibition
P-glycoprotein, playing a key role in drug resistance
[75]. Kreuter et al. suggested that the apolipoproteins B
and E may be chiefly involved in the transport of
NP-bound drugs into the brain. They concluded that by
coating the NPs with polysorbate 80, apolipoproteins
B and E get adsorbed onto the NP surface from the
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particles that could be taken up by the brain capillary
endothelial cells via receptor-mediated endocytosis
[76-78].
After endocytosis, drugs may be released within the
endothelium cells and undergo further transportation
into the brain by diffusion or through transcytosis [27].
For instance, Liu et al. used chelator-NP system and the
chelator-NP system complexed with iron to devise effec-
tive therapeutic strategy for Alzheimer’s disease which is
characterized by dyshomeostasis of metal ions with
abnormally high levels of iron in affected areas of the
brain [79]. They reported preferential adsorbtion of apo-
lipoprotein E and apolipoprotein A-I in the in vitro stu-
dies, thereby suggesting the RME transport of chelators
and chelator-metal complexes by the NPs across the
BBB. Further studies are needed to investigate whether
these metal chelators conjugated to NPs can play a role
in solubilizing amyloid- [beta] deposits in Alzheimer dis-
ease. This can open new pathways to the treatment of
neurodegerative diseases and also to study the ways of
neural repair using efficiently conjugated nanocarrier
system.
Kim et al. recently reported the blocking of low-density
lipoprotein receptors (LDLR). Their study is based on
brain endothelial cells involving cellular internalization of
Poly(methoxy-polyethyleneglycol cyanoacrylate-co-hexa-
decyl-cyanoacrylate) (PEG-PHDCA) NPs preincubated
with apolipoprotein E. It strengthens the hypothesis
of the preponderant role of the LDLR-mediated transport
Figure 3 Mechanisms of drug transport through the BBB using nanocarriers conjugated to receptor-specific ligands and cationized
ligands. (1) Receptor-mediated endocytosis of the nanocarrier; (1a) Exocytosis of the nanocarrier; (1b) Dissociation of the receptor from the
ligand-conjugated nanocarrier and acidification of the vesicle leading to the degradation of the nanocarrier and the release of the drug into the
brain; (1c and 1d) Recycling of receptors at the luminal cytoplasmic membrane; (2a) Adsorptive-mediated endocytosis of the nanocarrier
conjugated to cationized ligands; (2b) Exocytosis of positively charged nanocarriers (adapted from [66]).
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tamine-oligonucleotide NPs (proticles) coated with Apo-
lipoprotein A-I (apoA-I), Kratzer et al. observed
increased particle uptake and transcytosis in an in vitro
model of the BBB [81]. These findings were further sup-
plemented by Petri et al. who used Poly(butyl cyanoacry-
late) NPs coated with poloxamer 188 (Pluronic® F68)
bounded to doxorubicin and reported enhanced anti-
tumour effect of doxorubicin against an intracranial glio-
blastoma in rats [82]. They hypothesized that this may be
facilitated by the interaction of apolipoprotein A-I, pre-
sent on the surface of the NPs, with the scavenger recep-
tor class B, type I, the prime receptor for high density
lipoprotein/apoA-I that is expressed on brain capillary
endothelial cells (BCEC) [81]. Further research is
required to reveal the mechanisms behind the interaction
between SR-B1 and apoA-1 and their possible role in
enhancing the drug delivery via RME pathway. Moreover,
the possibility of more than one mechanism, implicated
in the interaction of nanocarrier based drug delivery sys-
tems with the brain endothelial cells, cannot be ruled out
[83].
In a novel approach, Demeule et al. reported the
design of a family of Kunitz domain-derived peptides
called Angiopeps as a potential brain drug delivery sys-
tem. Using a in vitro model of the BBB and in situ brain
perfusion, they demonstrated that these peptides, and in
particular Angiopep-2, exhibited higher transcytosis
capacity and parenchymal accumulation than other
receptors such as transferrin, lactoferrin, and avidin.
Furthermore, they suggested that the Angioprep-2 endo-
cytosis may be mediated by the low-density lipoprotein
receptor-related protein-1 (LRP1) [84].
Adsorptive-mediated endocytosis
Adsorptive-mediated endocytosis (AME) is a transport
mechanism that has gained significant importance
recently, and many new drug delivery technologies focus
on AME [61,85]. The underlying principle of AME
based transport is the electrostatic interaction between a
positively charged substance (e.g. cationized peptide
such as albumin) and the negatively charged sites on the
brain endothelial cell (BEC) surface (e.g. glycoprotein)
[61,86]. Dos Santos et al. studied the nature and distri-
bution of anions on the BEC surface in vitro and in situ
and found that the the predominant anion detected on
B E Cw a sh e p a r a ns u l p h a t e( H S )i nc o m p a r i s o nt ot h e
anionic locations observed in endothelia from aorta and
epididymal fat micro-vessels [87].
The hypothesis that phagocytic cells of the innate
immune system, mainly neutrophils and monocytes, can
be exploited as transporters of drugs to the brain has
been studied by Afergan et al. in vitro,i nr a t sa n dr a b -
bits by using negatively-charged nano-sized liposomes
with double-radiolabeled 3H (in the membrane) and
14C-serotonin (in the core), and fluorescent markers
(membrane and core) [88]. They observed a higher
brain uptake of liposomal serotonin, 0.138% ± 0.034 and
0.097% ± 0.011, vs. 0.068% ± 0.02 and 0.057% ± 0.01,
4 h and 24 h after IV administration in rats, serotonin
liposomes and in solution, respectively. They concluded
that monocytes act as key players for the transport of
serotonin liposomes.
Alkaloids like cocaine are well-known stimulants of the
central nervous system, and its effect upon the BBB has
been studied extensively. Alas, little exploited for drug
delivery, it actually relaxes tight junctions and induces
leukocyte migration. For instance, Liu et al. reported
enhanced BBB permeability and pharmacological activity
of the endogenous opioid receptor agonist, endomorphin
(EM)-1[68]. A series of EM-1 analogs were tested, e.g.
N-terminal cationization, C-terminal chloro-halogena-
tion, and unnatural amino acid (D-Ala, Sar, and D-Pro-
Gly) substitutions in position 2. They found that in com-
parison with EM-1, the four D-Ala-containing tetrapep-
tides and the chloro-halogenated D-Pro-Gly-containing
pentapeptide elicited significant and prolonged central-
mediated analgesia upon subcutaneous administration.
This fact might be interpreted as more peptides reaching
the CNS, thus bringing greater analgesic effect. They also
reported that the guanidino- [D-Ala2, p-Cl-Phe4]EM-1
showed 3 times more analgesia than the parent peptide
following intra cerebral-ventricular injection.
Adsorptive-mediated transport (AME) based transport
has been exploited to facilitate gene delivery into brain
tumours. Lu et al., for instance, has incorporated plasmid
pORF-hTRAIL (pDNA) into cationic albumin-conjugated
PEGylated NPs (CBSA-NP) to evaluate the efficacy of
CBSA-NP-hTRAIL as a nonviral vector for gene therapy
of gliomas [86]. They observed that 30 minutes after IV
administration of CBSA-NP-hTRAIL to BALB/c mice
bearing IC C6 gliomas. These NPs co-localized with gly-
coproteins in brain and tumour microvasculature. And,
more importantly, cells accumulated in tumour cells. In
addition, they reported apoptosis of brain tumour cells
in vivo and significantly delayed tumour growth. The
above results suggest adsorptive-mediated transport is a
very promising route of drug and gene delivery across
BBB for CNS disorders. More investigation is required to
explore other anionic sites on the BEC surface that can
be used to design efficient strategies for delivery using
nanocarrier systems through adsorptive-mediated trans-
port. Despite of possessing a lower affinity than RME,
AME provides a higher capacity than receptor-mediated
endocytosis.
As a field on its own, nano-drug delivery requires
proper functionalization, profound knowledge of the
range of possible routes to and from the central nervous
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nanocarriers reach their final destination. We proceed
to review some of the most exciting trends in functiona-
lization, delivery and imaging of nanomaterials.
NP mediated brain delivery systems
Before starting with the functionalization of NPs, it is
i m p o r t a n tt ok e e pi nm i n dar a n g eo fu s e f u lp r o p e r t i e s
we wish to have in any drug delivery across the BBB. In
this context, owing to their small size, customizable sur-
face, improved solubility, targeted drug delivery and
multifunctionality, NPs have emerged as potential drug
delivery carriers to tissues throughout the body [89]. Yet
passing the BBB is particularly difficult. The proper
design of such engineered ‘nanocarriers’ becomes very
important in transversing the impermeable membranes
to facilitate drug delivery. At the same time, it is also
required to retain the drug stability and ensure that
early degradation of drugs from the nanocarriers does
not take place.
Therefore, for drugs to be successfully delivered to
their target, many factors such as its size, biocompatibil-
ity, target specific affinity, avoidance of reticuloendothe-
lial systems, stability in blood, or ability to facilitate
controlled drug release need to be considered during
manufacture of the NPs. Ideal conditions, or wish-list, of
any drug are difficult to meet simultaneously. As for
nanocarriers to serve as good candidates for drug delivery
across the BBB can be summarized as follows [90,28]:
￿ particle diameter less than 100 nanometers;
￿ non-toxic, biodegradable and biocompatible;
￿ stable in blood (i.e., no opsonisation by proteins);
￿ BBB-targeted (i.e., use of cell surface, ligands, and
receptor mediated endocytosis);
￿ no activation of neutrophils, non-inflammatory;
￿ no platelet aggregation;
￿ avoidance of the reticuloendothelial systems;
￿ prolonged circulation time;
￿ scalable and cost effective with regard to manufac-
turing process;
￿ amenable to small molecules, peptides, proteins or
nucleic acids;
￿ controlled drug release or should exhibit modula-
tion of drug release profiles.
From materials science perspective, the design of such
nanocarriers becomes more complicated when it comes
to drug delivery to the brain because of its immunologi-
cally privileged characteristics which restricts the entry
of most pharmaceutical compounds across the BBB. As
such, the applicability of nanotechnology in CNS drug
delivery has been grossly limited and this may be attrib-
uted to the scarcity of strategies that can allow localized
and controlled delivery of drugs across the BBB to the
desired site of injury or impairment.
Functionalization and specificity of NPs
One of the most important challenges in nano-based
diagnostics and drug delivery is the functionalization of
NPs. Firstly, we need to develop effective conjugation
strategies to combine, in a highly controlled way, speci-
fic biomolecules to the surface of NPs. Figure 4 shows
an example of a PEGylated, multilayer NP (polyethylene
glycol, PEG, a popular choice for biocompatible
nanocarriers.
Some of the most prominent candidate biomolecules are
cell penetrating peptides (CPP) such as SynB vectors,
penetratin and Tat that facilitate enhanced intracellular
delivery [91-95], fluorescent dyes (rhodamine, alexa,
Cy5.5), tumoural markers for brain and gene therapeutic
agents for genetic therapy such as siRNA [96-101]. Figure 5
show two kinds of mouse tumour models, namely Xeno-
graft and genetically engineered mouse model (GEMM)
[102].
Functionalization itself requires a profound knowledge
of the target organ and its transport mechanisms. The
BBB has several transport molecules that can potentially
increase the efficiency and kinetics of nanocarriers
towards brains [103], such as, growth factors (e.g. epi-
dermal growth factor [58], vascular endothelial growth
factor [104], basic fibroblast growth factor [105], insu-
lin-like growth factors (IGF-I and -II) [106]), biotin-
binding proteins (avidin, streptavidin, or neutravidin)
[107], insulin [59,69], albumin [108-110], leptin
[111,112], lactoferrin [103,113], iron binding protein p97
(melanotransferrin) [114], transferrin [68,115] and
A n g i o p e p - 2[ 8 4 ] .S o m ea g e n t sp l a yap i v o t a lr o l ei n
enhancing the permeability of nanoprobes through BBB
[116-132]. A list of agents/condition and their effects on
BBB are summarized in Table 1.
Moreover, by altering the surface of polymeric NPs on
coating them with different hydrophilic surfactants, such
as polysorbate 80 (Tween® 80) or other polysorbates
with 20 polyoxyethylene units, biocompatible coatings of
non-viral gene delivery systems e.g. by poly ethylene gly-
col (PEG) attachment for siRNA delivery show signifi-
cant advantage in brain targeting [98].
NPs for drug delivery: Need of surfactants for BBB
transport
Due to its high specificity, NP provides an ideal platform
for the transport of drugs across the BBB. The current
status of some NP drug delivery platforms and the cor-
responding encapsulated drugs is summarized in Table
2. All entries refer to in vivo experiments.
NP-mediated drug transport to the brain strongly
depends on the type of surfactant. In Kreuter and
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onto the surface of poly (butylcyanoacrylate) (PBCA)
NPs were injected intravenously into mice to evaluate
the influence of surfactant on the analgesic effects. The
authors reported that only the NPs with polysorbate 20,
40, 60 and 80 coatings produced significant effect and
the maximum effect was observed for the PBCA NPs
bearing polysorbate 80 coating [133-136]. PBCA NPs
coated with surfactants have been successfully used in
the delivery of number of drugs across the BBB
[137,138], including the peptides (hexapeptide dalargin
and the dipeptide kytorphin), anti-tumour antibiotic
doxorubicin (DOX), loperamide, the NMDA receptor
antagonist MRZ 2/576, and tubocurarine [137-142].
Calvo et al. employed a novel strategy by using PEGy-
lated polycyanoacrylate, NPs (PEG PHDCA) as vector
for drug delivery in experimental model of Prion disease
[143]. The work showed that the PEG PHDCA particles
produced a higher uptake by the spleen and the brain
which are both the target tissues of PrPres (an abnormal
isoform which is characterized by the accumulation of
the host-encoded Prion protein (PrP) in the brain of
experimental Prion diseases mice) in comparison to the
non-PEGylated NPs. Wilson et al. have used polymeric
NPs for drug delivery of anti-Alzheimer’s drugs such as
tacrine and rivastigmine in the brain of rats [144,145].
Toxicity of conjugated drug-nanocarriers has always
been a concern. Gelperina et al. [139] studied the
Figure 4 Schematic representation of a multifunctional NP for diagnostics and drug delivery. Polyethylene glycol (PEG) copolymers are
one of the most popular vehicles for drug delivery. The NPs can be functionalized with suitable fluorescent markers, antibodies against tumoural
marker, gene delivery agents and drug molecules coated with a form of PEG. The antibody is using a long linking molecule that allows the
antibody to stick to PEG coatings. In contrast, cell penetrating peptides (CPP), employed to trigger rapid cell uptake, are attached using short
linkers.
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subcutaneously into immunodeficient mice. Oncogenes in GEMM are activated and/or tumour-suppressor genes (TSGs) are inactivated
somatically.
Table 1 Effect of different agent(s)/condition(s) on BBB
Agent/condition Effect on BBB Reference
Bradykinin, RMP-7 Transient increase of permeability, activates B2 receptors [116]
VEGF, HIF-1, Deferoxamine, Increase of permeability and leakage [117,118]
TNF-alpha, IL-1beta Moderate increase of permeability [119]
Tat, Nef, gp120 + IFN-gamma HIV-1-associated dysfunction [28-30,120,121]
Low magnetic field (0.15 T) Moderated increase of permeability [122,123]
Metalloproteinases Increase of permeability [124]
LTC4 Leukotriene-induced permeability [125,126]
Lipopolysaccharide Enhance the passage of regulatory proteins [127,128]
P85 Increase permeability by inhibiting the drug efflux transporter Pgp [129]
endothelin-1 Dramatic increase of permeability after intracisternal administration [130]
tPA Increase permeability via Akt phosphorylation [131]
PTX Increased permeability by altering endothelial plasticity and angiogenesis [132]
Table 2 NP based drug delivery systems: a list of NP conjugated platforms for delivery across the BBB
NP Platform Drug (and effects) References
PBCA NP coated with Polysorbate 80 dalargin (analgesic) [133,134,137]
PBCA NP coated with Polysorbate 80 doxorubicin (DOX) (anti-tumour antibiotic) [139,146,147]
PBCA NP coated with Polysorbate 80 kytorphin (analgesic) [141]
PBCA NP NMDA receptor antagonist MRZ 2/576 (antagonist) [140]
PBCA NP coated with Polysorbate 80 tubocurarine (Increased BBB permeability) [142]
PEG-PHDCA PrPres Specific Drug in Prion Disease [143]
PBCA NP coated with Polysorbate 80 tacrine (Anti Alzheimer’s Drug) [144]
PBCA NP coated with Polysorbate 80 rivastigmine (Anti Alzheimer’s Drug) [145]
PBCA NP coated with Polysorbate 80 gemcitabine (anti glioma drug) [148]
DMAEMA/HEMA (pH sensitive) paclitaxel [75]
LDC-polysorbate 80 NPs diminazene (anti human African trypanosomiasis (HAT)) [153]
DO-FUdR-SLN 5-fluoro-2’-deoxyuridine (FUdR) (Very efficient in brain targeting) [154]
PBCA NPs, MMA-SPM NPs, and SLNs stavudine (D4T), delavirdine (DLV), and saquinavir (SQV) (anti HIV agents and enhanced BBB
permeability)
[155]
PBCA NPs coated with apolipoprotein B
and E
loperamide and dalargin (increased BBB permeability) [77]
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NPs in healthy rats, and rats with intracranial glioblas-
toma. No drug-induced mortality occurred with a dose
of 3 × 1.5 mg/kg of the DOX NPs formulation on days
2, 5, 8 after tumour implantation. They concluded that
the toxicity of DOX bound to NPs was similar, or even
lower, than that of free DOX. Other studies aimed at
investigating the toxicological profile of doxorubicin
bound to NPs employing different dose regimens corre-
l a t e sw i t ht h er e s u l t so ft h i ss t u d y[ 1 4 6 ] .B a s e do nt h e
above findings, Pereverzeva et al. hypothesized that the
lower toxicity of the nanoparticulate formulation may
be due to the altered biodistribution of the drug
mediated by the NPs [146]. Wang et al. applied a unique
1% polysorbate-80 coated gemcitabine PBCA NPs
(GCTB-PBCA-NPs) to investigate its inhibitory effects
in C6 glioma cells in vitro and in vivo with Sprague
Dawley rats [147]. They observed significant increase in
the survival time of the rats injected with the formula-
tion compared with the saline control (P < 0.05).
In an interesting approach, You et al. [148] investigated
feedback regulated paclitaxel delivery by using pH-Sensi-
tive poly (N, N-dimethylaminoethyl methacrylate
(DMAEMA)/2-hydroxyethyl methacrylate (HEMA)) NPs
for the triggered release of paclitaxel within a tumour
microenvironment. Driven by the fact that the tumours
exhibit a lower extracellularp Ht h a nn o r m a lt i s s u e s ,
the authors found that the paclitaxel release from
DMAEMA/HEMA particles can be actively triggered by
small, physiological changes in pH (within 0.2-0.6 pH
units). It seems to be a promising way to facilitate drug
delivery by regulating the tumour microenvironment.
Further studies are thus required to explore other factors
within tumour microenvironment that can be exploited
to enable controlled release of drugs in brain tumours.
Drug delivery to the brain using Lipid NPs
Liposomes and related lipid structures have long been
employed for drug delivery. Lipid NPs, however, are
alternative carrier system to traditional colloidal carriers,
such as emulsions, liposomes and polymeric particles.
These novel carriers have been employed for brain
tumour targeting purposes and reviewed in [76]. NPs
based on solid lipids come in different types such as
“solid lipid NPs” (SLN), “nanostructured lipid carriers”
(NLC) and “lipid drug conjugate” (LDC) [149,150]. The
breakthrough in advanced conjugation strategies have
further led to the emergence of the newer forms of SLN
such as polymer-lipid hybrid NPs, nanostructured lipid
carriers and long-circulating SLN [151]. Because of its
physiochemical characteristics, SLNs have been very
successful in comparison to polymeric NPs due to the
lower cytotoxicity, higher drug loading capacity, and
best production scalability [152].
Back in 2002, Olbrich et al. reported, for the first time,
the use of LDC-polysorbate 80 NPs for brain delivery of
diminazene to treat second stage human African trypa-
nosomiasis (HAT) [153]. They obtained NPs with a very
high drug load of 33% (w/w), despite of the highly
water-soluble drug diminazenediaceturate. They con-
cluded that by transforming water-soluble hydrophilic
d r u g si n t oL D C ,N P sg o tp r o l o n g e dd r u gr e l e a s ea n d
targeting to specific sites by intravenous injection. In an
another study published shortly afterwards, Wang et al.
synthesized 3’,5’-dioctanoyl-5-fluoro-2’-deoxyuridine
(DO-FUdR) and incorporated it into solid lipid NPs
(DO-FUdR-SLN) by a thin-layer ultrasonication techni-
que in order to deliver the drug 5-fluoro-2’-deoxyuridine
(FUdR) to the brain. With the average particle size of
76 nm, drug loading of 29.02% and entrapment effi-
ciency of 96.62%, DO-FUdR-SLN proved to be very effi-
cient in in vivo brain targeting [154].
More recently, Kuo et al. evaluated the permeability of
anti-human immunodeficiency virus (HIV) agents,
including stavudine (D4T), delavirdine (DLV), and
saquinavir (SQV), across an in vitro model of BBB and
incorporating them with PBCA NPs, methylmethacry-
late-sulfopropylmethacrylate (MMA-SPM) NPs, and
SLNs. Their experimental results revealed an enhanced
BBB permeability [155]. Their work suggests that the
PBCA, MMA-SPM, and SLNs seem promising for the
drug delivery and clinical applications in neuro-AIDS
treatment.
Alternatives routes to drug delivery to the brain
No review of drug delivery across BBB is complete with-
out looking at the broad picture of administration
routes. A direct drug administration to the brain region,
painless and safe, will definitively improve the scenario.
However, in the meantime intravenous administration
is most popular choice in clinical studies. Some
approaches, however, that have been gaining consider-
able attention, such as oral route, inhalation or intra-tra-
cheal instillation (IT), intranasal drug delivery,
convection-enhanced diffusion and intrathecal/intraven-
tricular drug delivery systems in addition to the conven-
tional modes like intravenous administration. Therefore,
the administration route of NPs becomes an important
criterion of consideration so as to overcome the physio-
logical barriers of the brain and to achieve high drug
concentrations therein [58,156-161].
Interestingly, Semmler-Behnke et al. have recently
reported the uptake of 1.4 and 18 nm gold NPs in second-
ary target organs like the brain following intra-tracheal or
intravenous application [158]. Moreover, Wang et al. used
fluorescence-labeled bovine serum albumin (FBSA) loaded
in biodegradable poly(lactic acid-co-glycolic acid) (PLGA)
for intraspinal administration of Glial cell line derived
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cord injury (SCI) and for in vitro study [162]. PLGA-FBSA
NPs were well absorbed by neurons and glia, indicating
that PLGA as a considerable nanovehicle for the delivery
of neuroprotective polypeptide into injured spinal cord.
Also, local administration of PLGA-GDNF effectively pre-
served neuronal fibers and led to the hind limb locomotor
recovery in rats with SCI. The research opened a
new route nanocarrier administration by intraspinal
administration.
Two different modes of NP administration in brain
tumour mouse models are shown in Figure 5. Once
administered the NPs, they reach the site of tumour,
and localize it. Once they cross the BBB, the specific
ligands or peptides get attached to the specific surface
markers expressed on the tumours. Hence, by functiona-
lising NPs with fluorescent dyes could naturally provide
in vivo imaging of the ongoing biological events during
the drug administration as well may act as potential
diagnostics labels for early detection and localization of
brain tumours.
In vivo pharmacokinetics, biodistribution and safety of NP
mediated drug delivery system
Within the requirements of size and charge of effectively
deliver drugs via NP carrier systems, there are other chal-
lenges that need further attention. Although, much of the
work has been focused towards drug delivery with NPs,
relatively few studies have focused on the interaction of
NPs and their hosts in terms of biodistribution, organ
accumulation, degradation and/or toxicology like possible
damage of cellular structures or inflammatory foreign
body effects. Nanomedicine may find itself at crossroads.
It might not be wise to ignore possible adverse effects or
toxicity of nanocarriers [4,8,163-165].
Till recently, no pan-European initiative was addres-
sing these concerns. Noteworthy, the European Com-
mission has established the Registration, Evaluation,
Authorisation and Restriction of Chemical substances
(REACH) which provide safety regulation on substances.
Further, Borm et al. have extensively reviewed the
potential risks of use of NPs, in a review report commis-
sioned under the European Centre for Ecotoxicology
and Toxicology of Chemicals (ECETOC) [166]. We do
expect similar commissions worldwide shortly. Nano-
drug delivery is seen in its infancy, and works are mostly
focusing on particular aspects rather than holistic
approaches, e.g. ADME or DMPK. Well-established
research protocols like absorption, distribution, metabo-
lism and elimination (ADME), and drug metabolism and
pharmacokinetics (DMPK) will surely be part of nano-
drug delivery research in the near future [167].
On the distribution side, for instance, Kreyling et al.
have extensively studied translocation kinetics and particle
size dependency of NPs [77,164,168-170]. In general, smal-
ler NPs show superior translocation kinetics. But, because
of their small size might on the other hand cause toxicolo-
gical effects, see a review by Oberdörster [171]. It is all
about a trade-off between drug potency and immunologic
surveillance. For example, NPs of size <100 nm need to be
used to circumvent macrophage clearance in the lungs
[172]. Furthermore, several authors have reported that
intrinsic characteristics of NPs, such as aspect ratio and
surface area, can be pro-oxidant and pro-inflammatory
[31,165,173,174]. Here, the ultra high surface to mass ratio
together with new, and often unexpected nanosize specific,
material properties related to extreme radii of curvature
deserve closer attention [175,176]. Therefore, the use of
biopersistent carbon-based, e.g. single or multi-wall carbon
nanotubes, or metallic nanocarriers in nano medicine is
debatable. These important findings need not discourage
genuine efforts in nanodrug delivery, but strength the
selection process of materials, shapes and surface treat-
ments [3,4,8,164]. Biodegradable, non-toxic multi-block
co-polymers like those based on poly(image-lysine), PEG
copolyester and nanogels (e.g. polyethylenimine-PEG) are
thus advantageous.
Depending on their functionalization, biodegradable
nanocarriers can take a number of paths within tissues.
What are the possible trajectories nanocarriers take
inside the brain? Pharmacokinetics and excretion are
key points that demand an exhaustive research. Figure 6
shows the main ways drugs and nanocarriers take within
the extra cellular space of the brain. Following their
release, drugs can take different mechanisms and may
be transported within (and outside) the brain. One of
the mechanisms is their transport by diffusion due to
drug concentration gradients as shown in Figure 6 (i);
or they may be transported because of the convection
due to fluid pressure gradients (ii). Figure 6 (iii, a)
shows drug migration into ventricular space via pial or
ependymal surface. The drug molecules may also
undergo circulation in the sub-arachnoid mater or ven-
tricular spaces (iii, b). Subsequently, it is possible to dif-
fuse back into the brain interstitium (iii, c). The drug
molecules may also undergo permeation through the
endothelium (iv, a); followed by the circulation in the
cerebral blood vessels (iv, b); and eventually may re-
enter the brain interstitium by permeation (iv, c) [177].
The exact path, drugs and biodegradable nanocarriers
take, depends on many factors and its in vivo imaging is
perhaps the next milestone for nanodrug delivery, as
discussed in the following section.
Towards development of neurodiagnostic
nanoimaging platform
With the advent of multifunctional NPs, the field of brain
imaging is encountering a drastic change in the ways one
Bhaskar et al. Particle and Fibre Toxicology 2010, 7:3
http://www.particleandfibretoxicology.com/content/7/1/3
Page 13 of 25can monitor events at molecular and cellular level as well
as to track the development of neurological diseases, can-
cerous formations etc. One important aspect is develop-
ment of suitable imaging platforms that can be used to
trace these agents in vivo. Many of the well-established
modalities like positron emission tomography (PET), single
photon emission computed tomography (SPECT), MRI,
CT, as well as a variety of optical-contrast-based imaging
approaches, such as bioluminescence imaging, fluores-
cence molecular tomography (FMT), and optoacoustic
tomography, have gained considerable interest and applic-
ability in neurological research. In the following section,
we will focus on some of the commonly used techniques
with a special emphasis on the rapidly emerging optical
and optoacoustic in vivo molecular imaging techniques as
well as some trends in multimodality imaging approaches.
To better introduce the reader into the modern light-
based imaging modalities, we first provide a brief overview
of their basic principles of operation and main perfor-
mance characteristics of the most recent techniques.
Figure 6 Fate of drug released from the ‘Nanocarrier’ systems into the brain. The main ways drugs and nanocarriers take within the extra
cellular space of the brain. (adapted from [177]).
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Over the last three decades, X-Ray CT, MRI, and PET
have been commonly utilized for visualization of distri-
bution and therapeutic effects of drugs.
X-Ray CT has emerged as a major imaging modality
for imaging pharmacokinetics and treatment monitoring,
mainly based on indirect tracking of morphological
changes. For instance, Rabin et al. reported enhanced in
vivo imaging of the vasculature, the liver and lymph
n o d e si nm i c eu s i n gap o l y m e r - c o a t e dB i 2S3 NP formu-
lation as an injectable CT imaging agent [178]. Maier-
Hauff et al. used CT in order to noninvasively monitor
the local drug release in a rabbit radiofrequency (RF)
ablation model [179]. Overall, the application of NP
based imaging probes to X-ray CT imaging could have a
significant impact on health care, owing to the ubiqui-
tous nature of CT in the clinical setting as well as the
increasing use and development of micro-CT and hybrid
systems that combine PET and SPECT with X-ray CT.
Most common CT contrast agents are based on small
iodinated molecules, which are indeed effective in
absorbing X-rays; but nevertheless, their non-specific
distribution, rapid pharmacokinetics and low sensitivity
have rather limited their targeting performance.
With the distinct advantage of functional-imaging cap-
abilities as well as better contrast among soft tissues in
comparison to the CT, MRI has emerged as a tool in
oncological imaging and imaging of the diseased nervous
system [180]. Yet, MRI has relatively low sensitivity to
exogenous agents, therefore the choice of contrast
approaches is of paramount importance in the field of in
vivo brain imaging. Manganese is gaining importance as
T1 contrast neural tracer for MRI. In this role, it was
used to study three-dimensional (3-D) connectivity pat-
terns in the rat somatosensory system in vivo [181]. To
this end, magnetic NPs (MNPs) are of considerable inter-
est as contrast agents for MRI and carriers for drug deliv-
ery [182]. Superparamagnetic iron oxide NPs (SPIONs),
paramagnetic contrast agent (gadolinium) or perfluoro-
carbons have already been established as major players in
tracking single or clusters of labeled cells within target
tissues [183]. Multifunctional nanoplatforms, based on
protein cage architectures loaded with imaging agents
(fluorophore and MRI contrast agent) onto cells, have
also been developed for both diagnostics and targeted
treatment [184]. By including gadolinium-loaded lipo-
somes (GDL) with adeno-associated viral vectors (AAV),
real time MRI imaging and tracking of convection-
enhanced delivery (CED) of viral vectors to the three dif-
ferent regions of non-human primate brain (corona
radiata, putamen and thalamus) was achieved [185].
Another non-invasive imaging technology, the positron
emission tomography (PET), enables visualization of bio-
distribution of positron emitter-labelled compounds.
PET has certain advantages over CT and MRI, because of
its high sensitivity. For instance, Ukrami et al. [186]
designed labelled lipid NPs to study in vivo distribution
of liposome-encapsulated haemoglobin determined by
PET. Plotkin et al. [187] employed PET for targeting the
intra-tumourally injected magnetic NPs in patients with
glioblastoma. Indeed, since its introduction in the late
70’s, PET has become a powerful imaging modality with
the ability for highly sensitive detection of molecular tra-
cers and is currently utilized in diagnosis, therapy moni-
toring, and imaging gene expression using diverse
reporter genes and probes. However, high costs and
other complications associated with PET and SPECT
equipment limit their applicability. Moreover, the images
acquired by these techniques have poor spatial resolution
and hence accurate identification of regions of uptake is
difficult to achieve.
In summary, high costs, low sensitivity, and/or low
spatial resolution associated with the existing well-
accepted clinical imaging modalities promoted the
search for new approaches for in vivo visualization of
brain-targeting nanocarriers, such as methods based on
highly sensitive and specific optical contrast.
Optical imaging
Imaging with light has unique advantages associated with
simplicity, low-cost and small size of the equipment. Visi-
ble and near-infrared wavelengths offer many probing
mechanisms and highly specific contrast approaches not
available for other modalities. These can be used for vari-
ety of interrogations, from intrinsic functional informa-
tion on blood oxygenation to molecular sensing [188].
The light radiation is non-ionizing, and therefore reason-
able doses can be repeatedly employed without harm to
the animal or patient. Optical contrast methods offer the
potential to differentiate between soft tissues, due to
their distinct light absorption spectra otherwise indistin-
guishable using other modalities. Also, specific absorp-
tion by natural chromophores (such as oxy-haemoglobin)
allows functional information to be obtained. The use of
extrinsically-administered “switchable” and “tumour-
selective” fluorescent optical agents further advances the
application possibilities by allowing visualization of
otherwise invisible cellular and sub-cellular processes
[189-191].
During the last decade, a large number of commer-
cially available fluorescent probes and markers are
increasingly being offered, from non-specific fluorescent
dyes and fluorescent proteins to targeted or activatable
photoproteins and fluorogenic-substrate-sensitive fluoro-
chromes to enable a highly potent field for biological
imaging. So far, these contrast mechanisms were proven
efficient in a number of clinical and small-animal appli-
cations, including probing of tissue hemodynamics
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tease up-regulation associated with cancer growth and
inflammation [195,196] continuous monitoring of the
efficacy of anti-cancer treatments and other therapeutic
drugs [197]. Since many of the probes are developed to
fluoresce in the near-infrared (NIR) optical window,
where optical absorption is very low so that light can
penetrate deeply, fluorescence imaging has been success-
fully translated from a microscopy level to whole body
small animal imaging and clinics [198,199]. The combi-
nation of such probes with optical imaging may yield a
unique, highly sensitive technology for in vivo and real-
time imaging of the expression patterns for various
enzymes, which are crucially involved in tumour forma-
tion and metastasis. A good example are various breast
cancer cell lines that have been identified to over-
express specific enzymes such as matrix metalloprotei-
nases [200], which are not over expressed in normal
cells.
Despite these advantages, optical imaging is severely lim-
ited by scattering: thick tissues diffuse and absorb light and
significantly reduce the resolution, penetration capabilities
and the overall image fidelity [201]. Even state-of-the-art
multiphoton microscopy [202] is usually limited to super-
ficial imaging up to a depth of 0.5-1 mm in most living tis-
sues. Recent efforts to image entire embryos for example
required naturally transparent specimen or special chemi-
cal treatment to clear them from scattering, which is only
suitable for post-mortem imaging. Some other macro-
scopic photographic approaches like epi-fluorescence suf-
fer from similar light diffusion limitations and therefore
have low penetration depth, lack quantification abilities,
and overall cannot accurately provide depth and size infor-
mation [203]. Yet, some diffuse optical tomography (DOT)
methods were developed that can provide volumetric
images of optical contrast in entire human brain [204]
with applications ranging from real-time functional neuro-
imaging to the detection of hematomas.
It its more advanced form, fluorescence-mediated
molecular tomography (FMT) illuminates the sample
under investigation at multiple projections and utilizes
mathematical models of photon propagation in tissues
to reconstruct the underlying imaging contrast in three
dimensions, based on distribution of fluorescent mole-
cular probes or fluorescent proteins [195-197,205]. Sev-
eral different implementations, developed over the past
years, have been successfully used to three-dimension-
ally image bio-distribution of fluorochromes in entire
animals, and determine molecular pathways of cancer,
neurodegenerative and cardiovascular disease, offering
quantitative imaging. Whole-body fluorescence tomogra-
phy of small animals works optimally in the near-IR
region where the lower tissue attenuation allows the
penetration of photons over several centimeters [206],
but provides low spatial resolution (e.g. on the order of
1 mm in case of whole-body imaging of mice). Figure 7a
gives a general schematic of state-of-the-art free-space
FMT scanner for in vivo tomographic imaging of small
animals [207].
FMT systems were so far successfully used in molecu-
lar imaging studies of brain disease. In one of the studies
[24], using near-infrared fluorescent molecular beacons
and inversion techniques that take into account the
diffuse nature of photon propagation in tissue, three-
dimensional in vivo images of protease activity in ortho-
pic gliomas were obtained. In this study, 2 × 10
5 cells (9L
or HT1080) were stereotactically implanted into unilat-
eral brain hemispheres of nude mice. Animals were then
intravenously injected with the cathepsin-B imaging
probe (2 nmol Cy 5.5 per animal). The experiments pre-
sented the ability of FMT to three-dimensionally and
quantitatively resolve fluorochromes in deep tissues and
follow their response over time (Figures 7b and 7c).
Multimodality and hybrid imaging based on optical
contrast
Some of optical imaging complications associated with
poor spatial resolution and lack of anatomical reference
can possibly be mitigated by a marriage between non-
invasive optical molecular imaging and other high reso-
lution anatomical imaging modalities such as MRI, or
X-Ray CT. The latter combination was recently
employed to study the progression of Alzheimer’sd i s -
ease in vivo using a fluorescent oxazine dye to quantify
amyloid- [beta] plaques in a transgenic murine model
[208]. The authors reported very accurate signal locali-
zation and correlation of in vivo results to ex vivo
images of excised brain (Figure 7d), thereby emphasizing
that FMT is not only a potential tool to study in vivo
molecular functions, but it can also provide precise
mapping of those functions onto high resolution animal
anatomy, simultaneously provided by X-Ray CT (Figure
7g). Furthermore, the CT information was used to build
a more precise forward model in the FMT image recon-
struction process, which also improved spatial resolution
and quantification performance of FMT, as can be seen
in Figure 7f that was reconstructed using prior struc-
tural information (priors) from CT as compared to Fig-
ure 7e made without image priors. Another multimodal
imaging study was demonstrated by McCann et al.
where FMT and MRI were combined to study structure
and function of small rodents [209]. Three-dimensional
multimodal images were fused to provide a volumetric
model of living mouse brains. Interestingly, this
approach allows continuous monitoring of tumour mor-
phology, progression and protease activity.
The main challenge for optical imaging of diffuse tis-
sues is degradation of the spatial resolution, which is
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imaged object grows, imaging resolution quickly deterio-
rates [210]. It is therefore possible to perform optical
tomography, e.g. FMT, through entire mice with high
sensitivity, but low resolution of about 1 mm or worse
[188,211]. Optoacoustic (or photoacoustic) tomography
is an alternative hybrid imaging modality that has
recently demonstrated unprecedented high-resolution
visualization of optical contrast deep in tissues of small
animals [25,212,213]. Optoacoustic imaging relies on
detection of ultrasonic signals induced by absorption of
pulsed light, thus, high optical absorption contrast can
be simultaneously combined with good spatial resolution
of ultrasound, not limited by light scattering in tissue.
The amplitude of the generated broadband ultrasound
waves reflects local optical absorption properties of tis-
sue. Unlike classical optical imaging, the spatial resolu-
tion here is not determined nor limited by light
Figure 7 Summary of different optical diagnostic techniques.( a) Schematic of free-space 360 degree projection FMT imaging system
(reprinted with permission from [207]). (b) - (g) In this study, 2 × 10
5 cells (9L or HT1080) were stereotactically implanted into unilateral brain
hemispheres of nude mice (reprinted with permission from [24]). Animals were then intravenously injected with the cathepsin-B imaging probe
(2 nmol Cy 5.5 per animal). (b) and (c) Axial and sagittal MR slices of an animal implanted with a tumour, which is shown in green after
gadolinium enhancement. (d), (e), and (f), Consecutive FMT slices obtained from top to bottom from the volume of interest shown on (c) by
thin white horizontal lines. (f) Superposition of the MR axial slice passing through the tumour a onto the corresponding FMT slice c after
appropriately translating the MR image to the actual dimensions of the FMT image. (h) - (k) In vivo FMT study of Alzheimer’s disease progression
using a fluorescent oxazine dye to quantify amyloid- [beta] plaques in a transgenic murine model (reprinted with permission from [208]).
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achieved by any other optical imaging technology devel-
oped so far. Originally, optoacoustic imaging of tissues
targeted endogenous tissue contrast, primarily resolving
oxy- and deoxy-hemoglobin and different vascular struc-
tures. Wang et al. demonstrated high resolution imaging
of vascular anatomy in the mouse brain with capability
to visualize, with high spatial resolution, functional para-
meters, e.g. blood oxygenation levels, deep in an intact
living mouse brain [212]. Much like the ultrasound,
optoacoustics can form images in real time, currently
in 2D but potentially also in 3D [214]. In this way,
it can be used for real time tracking of dynamic phe-
nomena, such as fast hemodynamic changes [215], bio-
distribution of diagnostic agents or pharmacokinetics.
However, recently good contrast was also obtained from
other biological tissues that do not contain haemoglo-
bin, like fat, bones, and other internal structures [216].
The method was so far used for high-resolution whole-
body visualization of several optically diffusive model
organisms whose sizes may vary from sub-millimeter up
t oac e n t i m e t e rr a n g e ,e . g .i n s e c t s ,w o r m s ,f i s h e s ,a n d
small mammals [25,216,217]. However, since optoacous-
tics was already successfully applied to brain imaging in
primates [218] and whole breast imaging in humans
[219], selected clinical implementations are also fore-
seen. Advantageously, spatial resolution in optoacoustics
can be kept relatively high (between 20-200 μm) for the
entire penetration range of several millimeters to centi-
meters of tissue.
In addition to offering rich intrinsic tissue contrast,
optoacoustic imaging can also be used to visualize exo-
genous molecular and functional markers. Naturally,
almost all materials in nature absorb light therefore can
become potential candidates for providing contrast in
optoacoustic imaging. For high contrast imaging, of spe-
cial interest are compounds having high molar extinc-
tion (absorption). Several dedicated agents were so far
exploited for enhancing contrast in optoacoustics. Gold
NPs of various shapes (nanorods, nanocages, nanoshells)
[220], were shown to increase optoacoustic signals in
vivo. Single-walled carbon nanotubes (SWNT) provide
an excellent contrast for optoacoustics and, when conju-
gated with peptides or other specific targeting com-
pounds, can be used as molecular contrast agent [221].
Clearly, many other dedicated contrast agents could
potentially be developed for optoacoustic imaging appli-
cations. However, additional studies are required to
address a variety of efficiency, BBB penetration capabil-
ities, dosing, safety and toxicity concerns associated with
those new contrast agents. Instead, many widely adopted
optical contrast agents, such as fluorochromes, can be
readily used by applying multispectral optoacoustic
tomography (MSOT) [25]. It uses pulsed illumination at
multiple wavelengths in order to spectrally identify
reporter molecules with distinct spectral signatures,
such as common fluorochromes or other chromophores
within the background tissue absorption. In this way,
various additional molecularly-relevant information
contained in the optical spectrum can potentially
be resolved such as fluorogenic or chromogenic bio-
markers associated with gene expression, morphogenesis
or decease progression. The method is capable of high
resolution 3D visualization of molecular probes, such as
common optical molecular probes and fluorescent pro-
teins, located deep in scattering living tissues [25,222]. It
can therefore simultaneously deliver anatomical, func-
tional and molecular information with both high resolu-
tion and penetration capabilities.
In conclusion, even though optoacoustic imaging
methods like MSOT are in their infancy from both tech-
nical and application standpoints, it is a rapidly emer-
ging field in the imaging sciences that can overcome
major limitations of optical imaging while retaining its
contrast and sensitivity advantages [223]. It is therefore
expected to drastically expand the capabilities of photo-
nic imaging in the field of in vivo imaging of drug deliv-
ery markers.
Naturally, every imaging modality comes with its own
pros and cons and no method can fulfill the complete
range of requirements for every application. Table 3
summarizes the main performance characteristics of dif-
ferent imaging modalities, related to their potential use
in real-time tracking of nanocarriers in the brain.
Discussion and future perspectives
Drug delivery across the BBB is already one of industry’s
most sought-after routes. Many ageing disorders and
tumours require drugs acting on the central nervous
system, and the number of patients looking for efficient
treatments is constantly increasing. Longer life expec-
tancy should also match better old-age life [224], how-
ever, current therapies fall short of the population’s
expectations. Anatomic features prevent most drugs to
be delivered to the CNS across the BBB. By overcoming
the physiological barriers of the brain, achieving higher
drug concentration will become indeed feasible, which
prompts an intensive search for alternative drug delivery
routes.
Multifunctional NPs allow delivering pharmaceutical
agents into the brain. We reviewed a range of endogen-
ous molecular pathways represented by growth factors,
e.g. insulin and transferrin, which when taken advantage
of, can increase the efficiency and kinetics of nanocar-
riers across the BBB. Multifunctional nanocarriers or
their combination with other drugs will drive the search
for targeting specific areas in the brain and thus
enhance therapies. Nanomedicine has yet to make its
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the accumulated experience in the field has reached its
critical mass.
Here, we have reviewed part of this exciting progress
and research advances within the context of drug deliv-
ery and in vivo imaging of multifunctional NPs. Those
nanocarriers can indeed be functionalized with drugs as
well as fluorescent substances therefore their diagnostics
and therapeutic potential is enormous. Imaging of func-
tion and molecular activity is at the frontier of current
research efforts to detect and study a variety of diseases,
such as cancer, in a less invasive way. A range of ima-
ging techniques was reviewed. We described well-estab-
lished radiological imaging techniques and highlighted
the recent developments on optical molecular imaging
approaches that exploit intrinsic and exogenous bio-
markers for in vivo gene expression profiling and visua-
lization of different molecular pathways. Imaging of
optical contrast can provide both high sensitivity and
specificity because background signals can effectively be
suppressed by using smart bio-markers, e.g. enzyme-
activated fluorescence probes. A proper combination of
optical techniques with conventional techniques like CT
and MRI can definitely enhance the ways one can quan-
titatively monitor structure, function and molecular
pathways, key features of neurological diseases. More-
over, recent advances in optoacoustic technologies hold
a great promise of overcoming scattering-related limita-
tions of optical imaging, eventually shifting the paradigm
of whole-body molecular imaging towards high resolu-
tion real-time performance.
For a successful nanomedicine approach, all three ele-
ments (functionalization, targeting and imaging) have to
be further developed. The interest in BBB has steadily
grown in recent years, as can be seen from over 5000
papers now listed in PubMed. From the vast literature
we concentrate on the inter-relations between functio-
nalization, targeting and imaging; each of these issues
deserving comprehensive reviews on their own. Their
proper combination can dramatically enhance spatial
and temporal resolution, thereby facilitating a unique
way to keep track on disease progression as well as on
the histological changes in the target tissues. Nanodrug
delivery and multimodal imaging could, in principle,
treat and monitor tumour status, thus increasing the
patient’s likelihood of survival.
The translation of NPs in clinical use for therapeutic
and diagnostics applications looks promising amidst the
recent developments. The field of nanopharmaceuticals
is an emerging area of great medicinal interest [225],
which aims at developing novel engineered nanoparticles
for pharmaceutical applications and show great promise
with varied range of applications such as in vaccination,
cell therapy and gene therapy [226]. For instance, nano-
particle based drugs gaining considerable interest in
pharmaceutical industry and already in clinical practice
are liposomal doxorubicin and albumin conjugate pacli-
taxel [227,228]. In an ongoing Phase I clinical trial at
UCSF, California, paclitaxel albumin-stabilized NP for-
mulation (nab-paclitaxel) is being used in treating
advanced cancers such as bladder cancer, brain and
CNS tumours, breast cancer, etc [229]. In addition,
many other NP based diagnostic and therapeutic agents
are in clinical trials [230], and future looks promising
for the fast growing field of nano diagnostics. Moreover,
further initiatives are required to boost the translation
of NP formulations from bench to clinics.
Multifunctional nanocarriers for drug targeting and in
vivo imaging are mature fields, with bright prospects to
bring much-needed treatments for neurodegenerative
pathologies. However, from a broader perspective, nano-
carriers loaded with multiple diagnostic, therapeutic or
targeting molecules can pave the way to successfully
deal with a large range of other diseases. Application of
multifunctional nanocarriers is one of the main driving
forces behind our renewed interest in the BBB. More-
over, it has helped to understand the mechanisms that
govern structural and composition changes in response
Table 3 Performance of different modalities applicable for depth-resolved (volumetric) imaging of the CNS.
Imaging method Anatomical
contrast
Molecular/Functional
contrast
Sensitivity to
contrast agents
Spatial
resolution
(*)
Penetration
depth
Cost Safety Applicability
X-Ray CT Medium Poor μmol (10
-6) 10-500 μm
scalable
Whole-body Medium Medium Pre-clinical/
Clinical
MRI Good Medium nmol (10
-9) 30-500 μm
scalable
Whole-body High Good Pre-clinical/
Clinical
PET/SPECT Poor Good fmol (10
-14) 1 - 5 mm Whole-body High Medium Pre-clinical/
Clinical
3D light microscopy Good Good fmol (10
-14) 0.2 - 10 μm Superficial (<1 mm) Medium Good Pre-clinical
FMT Poor Good pmol (10
-12) 1 - 2 mm ~20 mm Low Good Pre-clinical
MSOT microscopy/
tomography
Good Good pmol (10
-12) 5 - 200 μm
scalable
~30 mm Low Good Pre-clinical/
Clinical
(*) Spatial resolution usually depends on the overall size of the imaged object/area therefore a range is provided
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infective viruses like HIV-1, and potential BBB disrupt-
ing molecules. Clinical translation of these findings
should be fully exploited as to introduce nano-based
medicine, a cutting-edge technology poised to change
how medicine is administered.
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